Arbutus Biopharma Secures Mixed Ruling in Moderna Patent Case
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arbutus Biopharma ( (ABUS) ) has provided an announcement.
On February 2, 2026, the U.S. District Court for the District of Delaware issued a memorandum and order in the patent infringement litigation brought by Arbutus Biopharma and its licensee Genevant Sciences against Moderna over the use of lipid nanoparticle technology in the manufacture and sale of Moderna’s COVID-19 vaccine, mRNA-1273. The court rejected Moderna’s bid to have most of the dispute transferred to the Court of Federal Claims on the theory that it acted for the U.S. government under Operation Warp Speed, and found that factual questions about the validity of Arbutus’s patents must be decided by a jury, while also ruling that aspects of the patents’ prosecution history bar Arbutus from relying on the doctrine of equivalents for certain molar ratio claims, meaning Arbutus must prove literal infringement on those elements, a mixed outcome that keeps key infringement and validity issues alive but narrows Arbutus’s legal theories going into trial.
The most recent analyst rating on (ABUS) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
Spark’s Take on ABUS Stock
According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.
The score is primarily constrained by weak financial performance (large losses, negative margins, declining revenue, and negative operating/free cash flow). Technicals are also soft with the price below key short- and mid-term moving averages and weak momentum indicators. Valuation is less supportive due to a negative P/E, and corporate events add uncertainty due to litigation and patent-related risks.
To see Spark’s full report on ABUS stock, click here.
More about Arbutus Biopharma
Arbutus Biopharma is a biotechnology company focused on developing and commercializing lipid nanoparticle (LNP) delivery technologies for nucleic acid-based therapeutics and vaccines, including patents covering specific lipid molar ratios and methods for forming lipid vesicles that encapsulate nucleic acids such as mRNA.
Average Trading Volume: 1,415,010
Technical Sentiment Signal: Sell
Current Market Cap: $746.2M
See more insights into ABUS stock on TipRanks’ Stock Analysis page.
